Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating ...
Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19 did not meet primary endpoint of reducing hospitalization or death. Bemnifosbuvir was safe and well-tolerated. Atea focuses on bemnifosbuvir and ruzasvir combination for hepatitis C treatment.
Reference News
Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19 did not meet primary endpoint of reducing hospitalization or death. Bemnifosbuvir was safe and well-tolerated. Atea focuses on bemnifosbuvir and ruzasvir combination for hepatitis C treatment.
Atea Pharmaceuticals' Phase 3 SUNRISE-3 study of bemnifosbuvir for Covid-19 treatment did not meet primary goal of reducing hospitalization or death. Bemnifosbuvir is also in Phase 2 for HCV treatment with ruzasvir; additional results planned for Q4.